큐레이션 · 헬스케어

Biotech

InspectStocks 제공Published 2026년 10월 14일19 companies0 followers

Drug developers with approved medicines, built mainly on biologic and genetic science.

AI 모델의 도움으로 묶고 편집자가 검토했습니다. 각 기업 아래의 한 줄이 이 기업이 여기 있는 이유를 설명합니다.

Download image

카드 티어

주가는 2026년 11월 11일 종가이며, IEX 거래소 피드 기준입니다.

Grade mix

A 8B 4C 5D 1F 1

Revenue growing

18 of 19

Free cash flow growing

13 of 18

Median price move, 1 year

+29.0%

Sort by

VRTXVERTEX PHARMACEUTICALS INC / MA
BiotechnologyMarket cap US$138.7BP/E 35.22
US$547.02+26.0%1Y
Since added +12.7%
B+
성장과 현금
강하게 성장 중
Business trend
안정
Business quality
우수
Getting better
개선 중
Revenue
US$13B+10.5%
Profit
US$4B+8.2%
Free cash flow
US$3.2B-4.0%
Discuss
Why it is here: Develops and sells cystic fibrosis and other medicines
REGNREGENERON PHARMACEUTICALS, INC.
BiotechnologyMarket cap US$101.3BP/E 21.18
US$959.45+41.5%1Y
Since added +27.4%
C+
성장과 현금
성장 중
Business trend
가속
Business quality
우수
Getting better
개선 중
Revenue
US$16.9B+18.6%
Profit
US$4.8B+5.2%
Free cash flow
US$3.8B-9.4%
Discuss
Why it is here: Develops and sells antibody therapies for eye, allergy and cancer conditions
GILDGILEAD SCIENCES, INC.
Drug manufacturers generalMarket cap US$210.5BP/E 없음 (영업손실)
US$169.73+40.9%1Y
Since added +14.8%
A
성장과 현금
강하게 성장 중
Business trend
안정
Business quality
혼조
Getting better
개선 중
Revenue
US$31B+6.5%
Profit
-US$3.9B-147.6%
Free cash flow
US$13.8B+50.4%
Discuss
Why it is here: Sells medicines for HIV, liver disease and cancer
ALNYALNYLAM PHARMACEUTICALS, INC.
BiotechnologyMarket cap US$21.4BP/E 68.58
US$159.80-64.7%1Y
Since added -28.6%
B+
성장과 현금
강하게 성장 중
Business trend
둔화
Business quality
우수
Getting better
개선 중
Revenue
US$3.7B+65.2%
Profit
US$2.6B+2,136.9%
Free cash flow
US$465.4M+1,192.7%
Discuss
Why it is here: Develops and sells RNAi therapeutics
BIIBBIOGEN INC.
Drug manufacturers generalMarket cap US$37.5BP/E 109.22
US$253.39+56.9%1Y
Since added +10.7%
A
성장과 현금
강하게 성장 중
Business trend
안정
Business quality
양호
Getting better
혼조
Revenue
US$10.3B+2.3%
Profit
US$347.5M-78.4%
Free cash flow
US$2.1B-10.1%
Discuss
Why it is here: Develops and sells therapies for neurological diseases
INSMINSMED INC
BiotechnologyMarket cap US$26.5BP/E 없음 (영업손실)
US$120.64-37.9%1Y
Since added +24.7%
C-
성장과 현금
성장 중
Business trend
안정
Business quality
취약
Getting better
혼조
Revenue
US$1.5B+240.0%
Profit
-US$605.6M+48.8%
Free cash flow
-US$627.6M+30.7%
Discuss
Why it is here: Develops and sells therapies for rare lung diseases
UTHRUnited Therapeutics Corporation
Drug manufacturers specialty and genericMarket cap US$25.4BP/E 22.48
US$595.58+29.0%1Y
Since added +9.6%
C+
성장과 현금
강하게 성장 중
Business trend
둔화
Business quality
우수
Getting better
크게 개선 중
Revenue
US$3.2B+1.9%
Profit
US$1.2B-3.2%
Free cash flow
US$867.2M-22.7%
Discuss
Why it is here: Sells therapies for pulmonary arterial hypertension
NBIXNEUROCRINE BIOSCIENCES, INC.
Drug manufacturers specialty and genericMarket cap US$17.6BP/E 25.87
US$174.35+18.7%1Y
Since added +29.0%
A+
성장과 현금
강하게 성장 중
Business trend
가속
Business quality
우수
Getting better
개선 중
Revenue
US$3.7B+38.0%
Profit
US$702.5M+64.1%
Free cash flow
US$1B+75.3%
Discuss
Why it is here: Develops and sells therapies for neurological and endocrine disorders
MRNAModerna, Inc.
BiotechnologyMarket cap US$100.6BP/E 없음 (영업손실)
US$248.70+831.1%1Y
Since added +15.0%
C-
성장과 현금
성장 중
Business trend
가속
Business quality
취약
Getting better
악화 중
Revenue
US$2.5B+13.1%
Profit
-US$2.8B+10.5%
Free cash flow
-US$2B+25.7%
Discuss
Why it is here: Develops mRNA vaccines and therapies
BMRNBioMarin Pharmaceutical Inc
BiotechnologyMarket cap US$11.3BNo P/E
US$58.32+5.4%1Y
Since added +7.3%
B
성장과 현금
강하게 성장 중
Business trend
안정
Business quality
혼조
Getting better
개선 중
Revenue
US$3.7B+18.1%
Profit
-US$19.1M-103.7%
Free cash flow
US$557.9M-33.0%
Discuss
Why it is here: Develops and sells therapies for rare genetic diseases
INCYINCYTE CORPORATION
BiotechnologyMarket cap US$24.9BP/E 65.01
US$122.23+12.9%1Y
Since added +12.6%
C
이익과 순자산가치
성장 중
Business quality
혼조
Getting better
크게 개선 중
Revenue
US$6B+24.9%
Profit
US$403.4M-66.1%
Free cash flow
US$892.1MNo comparable year
Discuss
Why it is here: Develops and sells oncology and inflammation therapies
EXELEXELIXIS, INC.
BiotechnologyMarket cap US$17.3BP/E 21.17
US$70.71+62.2%1Y
Since added +18.8%
A+
성장과 현금
강하게 성장 중
Business trend
안정
Business quality
우수
Getting better
개선 중
Revenue
US$2.5B+9.1%
Profit
US$885.1M+30.6%
Free cash flow
US$1.2B+48.9%
Discuss
Why it is here: Develops and sells cancer therapies
BNTXBioNTech SE
BiotechnologyMarket cap US$22BP/E 없음 (영업손실)
US$87.64-21.5%1Y
Since added -1.5%
F
성장과 현금
혼조
Business trend
축소
Business quality
혼조
Getting better
개선 중
Revenue
US$2.7B-23.2%
Profit
-US$1.6B-157.7%
Free cash flow
US$314M+456.5%
Discuss
Why it is here: Develops mRNA vaccines and cancer therapies
JAZZJazz Pharmaceuticals plc
BiotechnologyMarket cap US$15.9BP/E 80.84
US$248.18+81.5%1Y
Since added +18.0%
A
성장과 현금
강하게 성장 중
Business trend
안정
Business quality
혼조
Getting better
개선 중
Revenue
US$4.7B+13.5%
Profit
US$206M+155.9%
Free cash flow
US$1.6B+21.3%
Discuss
Why it is here: Develops and sells neuroscience and oncology therapies
HALOHALOZYME THERAPEUTICS, INC.
BiotechnologyMarket cap US$11.6BP/E 25.36
US$101.69+44.0%1Y
Since added -7.2%
A+
성장과 현금
강하게 성장 중
Business trend
안정
Business quality
우수
Getting better
개선 중
Revenue
US$1.8B+45.0%
Profit
US$485.4M-18.5%
Free cash flow
US$885.9M+47.1%
Discuss
Why it is here: Licenses drug delivery technology and sells enzyme-based therapies
ASNDAscendis Pharma A/S
BiotechnologyMarket cap US$16.1BP/E 없음 (영업손실)
US$259.10+30.1%1Y
Since added +16.0%
D
이익과 순자산가치
혼조
Business quality
혼조
Getting better
개선 중
Revenue
US$1.2B+113.4%
Profit
-US$254.8M+39.7%
Free cash flow
-US$293.2M+54.2%
Discuss
Why it is here: Develops and sells endocrinology rare disease therapies
BBIOBridgeBio Pharma, Inc.
BiotechnologyMarket cap US$15.5BP/E 없음 (영업손실)
US$79.53+20.1%1Y
Since added +25.6%
B
성장과 현금
강하게 성장 중
Business trend
안정
Business quality
혼조
Getting better
악화 중
Revenue
US$945.5M+167.3%
Profit
-US$573.8M+28.6%
Free cash flow
-US$369.8M+36.9%
Discuss
Why it is here: Develops therapies for genetic diseases
CORTCORCEPT THERAPEUTICS INC
BiotechnologyMarket cap US$8.2BP/E 58.68
US$74.52-4.9%1Y
Since added -36.7%
A+
성장과 현금
강하게 성장 중
Business trend
가속
Business quality
우수
Getting better
혼조
Revenue
US$963.6M+30.0%
Profit
US$162.3M+52.9%
Free cash flow
US$194.6M+19.2%
Discuss
Why it is here: Develops and sells cortisol-modulating therapies
KRYSKrystal Biotech, Inc.
BiotechnologyMarket cap US$9.2BP/E 41.90
US$308.82+52.1%1Y
Since added -3.9%
A+
성장과 현금
강하게 성장 중
Business trend
안정
Business quality
우수
Getting better
개선 중
Revenue
US$470M+26.0%
Profit
US$225.2M+13.2%
Free cash flow
US$310.1M+87.3%
Discuss
Why it is here: Develops and sells topical gene therapies for rare diseases

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.